Comorbidity of Anxiety Disorders Chronic and Pain Syndromes: Especially Treatment
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Today proved comorbidity anxiety disorders and pain, and, as the clinical practice, chronic pain can cause anxiety and depressed mood accompanied by symptomatic persistent fears. Proven important role of dopamine in changes in pain sensitivity in patients with chronic disorders of the central nervous system. The change in pain sensitivity in patients with impaired dopamine activity in different clinical conditions could have important implications outcomes severity of pain, and changes in dopamine signaling mechanisms in chronic pain an opportunity to influence treatment strategy. In recent years, along with a wide noradrenalin study and serotonin receptors in the pathogenesis of depressive disorders spectrum, set the sensitivity of dopamine receptors and considerably more pronounced prolactin response to sulpiride administration in depression. Sulpiride belongs to a group of atypical neuroleptics and so in the early years of clinical study, most research has been directed to determine its effectiveness in psychotic disorders. Accumulation of current clinical data revealed wide spectrum efficiency sulpiride and its important differences from the classical neuroleptics.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Johanna M. Jarcho, Emeran A. Mayer, Karen Jiang et al / Pain, Affective Symptoms and Cognitive Deficits in Patients with Cerebral Dopamine Dysfunction // Pain. 2012 Apr; 153(4): 345-351.
Gureje O, Simon GE, Von Korff M. A cross-national study of the course of persistent pain in primary care. Pain. 2001;92:195-200.
Dworkin RH, Gitlin MJ. Clinical Aspects of Depression in Chronic Pain Patients. Clin J Pain. 1991:7.
Crombez G, Vlaeyen JW, Heuts PH, Lysens R. Pain-related fear is more disabling than pain itself: evidence on the role of pain-related fear in chronic back pain disability. Pain. 1999;80:329-339.
Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433-2445.
Magni G, Moreschi C, Rigatti-Luchini S, Merskey H. Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain. 1994;56:289-297.
Rhudy JL, Meagher MW. Fear and anxiety: divergent effects on human pain thresholds. Pain. 2000;84:65-75.
Tang NKY, Salkovskis PM, Hodges A, Wright KJ, Hanna M, Hester J. Effects of mood on pain responses and pain tolerance: an experimental study in chronic back pain patients. Pain. 2008;138:392-401.
Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci. 2006;7:818-827.
Rico-Villademoros F, Hidalgo J, Dominguez I, Garcнa-Leiva JM, Calandre EP. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:161-164.
Kernbaum S, Hauchecorne J. Administration of levodopa for relief of herpes zoster pain. JAMA: the journal of the American Medical Association. 1981;246:132-134.
Ertas M, Sagduyu A, Arac N, Uludag B, Ertekin C. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain. 1998;75:257-259.
Dickey RP, Minton JP. Levodopa relief of bone pain from breast cancer. The New England Journal of Medicine. 1972;286:843.
Garcia C, Lynn R, Breitbart W. Psychotropic medications in palliative care. Prim Psychiatry. 2009;16:25-32.
Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997;20:31-37.
Moore H, Todd CL, Grace AA. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci. 1998;18:5068-5077.
Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280:73-82.
Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. The Journal of Clinical Psychiatry. 2002;63:38-43.
Вельтищев Д.Ю. Многоликий Эглонил / Вельтищев Д.Ю // РМЖ. – 2001. – № 25. – С. 1197.
O’Connor SE. The pharmacology of sulpiride – a dopamine receptor antagonist / Brown RA // Gen. Pharmacol. – 1982. – 13. – Р. 185-193.
Mauri MC. A risk–benefit assessment of sulpiride in the treatment of schizophrenia / Bravin S, Bitetto A // Drug Saf. – 1996. – 5. – 14. – 288-298.
Ferreri M. Sulpiride: study of 669 patient presenting with pain psychological origin / Florent C, Gerard D // Encephale. – 2000. – 26. – 58-66.
Drago F. Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats / Arezzi A, Virzi A // Eur. Neuropsychopharmacology. – 2000. – 10. – 437-442.
Maier W. Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies / Benkert O // Psychopharmacology (Berl). – 1994. – 8. – 115. 495-501.
Ruter E. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial / Degner D, Munzel U // Pharmacopsychiatry. – 999. – 32. – 127-135.
Altamura AC.Sulpiride in the treatment of somatoform disturbances: a double-blind study with racemic sulpiride / Mauri MC, Regazzetti GL // Minerva Psichiatr. – 2000. – 32. – 25-29.
Данилов Д.С. Нейролептики-бензамиды в практике психиатра, невролога и интерниста на современном этапе развития психофармакологии (на примере сульпирида) / Д.С. Данилов // Неврология, нейропсихиатрия, психосоматика. – Выпуск № 3. – 2012. – С. 77-84.
Ho C.S. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder / Chen H.J., Chiu N.C // J Form Med Assoc. – 2009. – 108 (10). – 788-93.
Vilyanov VB. The efficacy of sulpiride in patients with anxiety disorders depending on the serum serotonin concentrations / Kremenitskaya SA, Soloveva NV // Zh Nevrol Psikhiatr Im S S Korsacova. 2015. – 115 (10). – 62-5.
Viviane Muniz da Silva Fragoso. Binding of Sulpiride to Seric Albumins / Carla Patrícia de Morais Coura, Luanda Yanaan Hoppe, Marília Amável Gomes Soares, Dilson Silva, Celia Martins Cortezl // Int J Mol Sci. – 2016 Jan. – 17 (1). – 59.
